Enhanced cellular uptake and biodistribution of a synthetic cannabinoid loaded in surface-modified poly(lactic-co-glycolic acid) nanoparticles

Journal of Biomedical Nanotechnology

Volumn 10, Issue 6, 2014, Pages 1068-1079

  Durán Lobato, Matilde ^a   Muñoz Rubio, Inmaculada ^a   Holgado, M Ángeles ^a   Álvarez Fuentes, Josefa ^a   Fernández Arévalo, Mercedes ^a   Martín Banderas, Lucía ^a  

^a UNIVERSITY OF SEVILLE   (Spain)

Author keywords

Cannabinoid agonist; Nanoparticles; Oral absorption enhancers; Poly(lactic co glycolic acid); Surface modified

Indexed keywords

CHITOSAN; COPOLYMERS; DRUG PRODUCTS; LECITHIN; SIZE DISTRIBUTION; ZETA POTENTIAL;

CANNABINOID AGONIST; ENTRAPMENT EFFICIENCY; MUCOADHESIVE PROPERTIES; NANOPRECIPITATION METHOD; ORAL ABSORPTION; POLY LACTIC-CO-GLYCOLIC ACID; SURFACE MODIFYING AGENT; SURFACE-MODIFIED;

NANOPARTICLES;

ALPHA TOCOPHEROL; CANNABINOID; CHITOSAN; EUDRAGIT RS; NAPHTHALEN 1 YL (4 PENTYLOXYNAPHTHALENFROM 1 YL)METHANONE; PHOSPHATIDYLCHOLINE; POLYGLACTIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL STRAIN CACO 2; CELL VIABILITY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG RELEASE; DRUG UPTAKE; EX VIVO STUDY; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; MUCOADHESION; NONHUMAN; PARTICLE SIZE; RAT; ZETA POTENTIAL;

ADMINISTRATION, ORAL; ANIMALS; CANNABINOIDS; LACTIC ACID; MALE; MATERIALS TESTING; MICE; MICE, INBRED C57BL; NANOCAPSULES; ORGAN SPECIFICITY; PARTICLE SIZE; POLYGLYCOLIC ACID; SURFACE PROPERTIES; TISSUE DISTRIBUTION;

EID: 84898493106     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2014.1806     Document Type: Article

References (45)

1. P. Robson, Therapeutic aspects of cannabis and cannabinoids. Therapeutic. Brit. J. Pharmacol. 178, 107 (2001).
2. M. Ben-Amar, Cannabinoids in medicine: A review of their therapeutic potential. J. Ethnopharmacol. 105, 1 (2006).
3. E. Busso, Cannabinoids in the management of difficult to treat pain. Therapeut. Clin. Risk Manag. 4, 245 (2008).
4. D. Hernán Pérez de la Ossa, A. Ligresti, M. E. Gil-Alegre, M. R. Aberturas, J. Molpeceres, V. Di Marzo, and A. I. Torres Suárez, Poly-ε-caprolactone microspheres as a drug delivery system for cannabinoid administration: Development, characterization and in vitro evaluation of their antitumoral efficacy. J. Control Release 161, 927 (2012).
5. Y. Zhang, X. Wu, L. Meng, Y. Zhang, R. Ai, N. Qi, H. He, H. Xu, and X. Tang, Thiolated Eudragit nanoparticles for oral insulin delivery: Preparation, characterization and in vivo evaluation. Int. J. Pharm. 436, 341 (2012).
6. L. Martín-Banderas, J. Álvarez-Fuentes, M. Durán-Lobato, J. Prados, C. Melguizo, M. Fernández-Arévalo, and M. A. Holgado, Cannabinoid derivate-loaded PLGA nanocarriers for oral administration: Formulation, characterization and cytotoxicity studies. Int. J. Nanomed. 7, 5793 (2012).
7. A. des Rieux, V. Fievez, M. Garinot, Y. J. Schneider, and V. Préat, Nanoparticles as potential oral delivery systems of proteins and vaccines: A mechanistic approach. J. Control Release 116, 1 (2006).
8. A. Gardin, K. Kucher, B. Kiese, and S. Appel-Dingemanse, Cannabinoid receptor agonist 13, a novel cannabinoid agonist: First in human pharmacokinetics and safety. Drug Metab. Dispos. 37, 827 (2009).
9. E. K. Dziadulewicz, S. J. Bevan, C. T. Brain, P. R. Coote, A. J. Culshaw, A. J. Davis, L. J. Edwards, A. J. Fisher, A. J. Fox, C. Gentry, A. Groarke, T. W. Hart, W. Huber, I. F. James, A. Kesingland, L. La Vecchia, Y. Loong, I. Lyothier, K. McNair, C. O'Farrell, M. Peacock, R. Portmann, U. Schopfer, M. Yaqoob, and J. Zadrobilek, Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl) methanone: A potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration. J. Med. Chem. 50, 3851 (2007).
10. M. M. Issa, M. Koping-Hoggard, and P. Artursson, Chitosan and the mucosal delivery of biotechnology drugs. Drug Discovery Today Technol. 2, 1 (2005).
11. P. C. Naha, V. Kanchan, P. K. Manna, and A. K. Panda, Improved bioavailability of orally delivered insulin using Eudragit-L30D coated PLGA microparticles. J. Microencap. 25, 248 (2008).
12. A. Lamprecht, P. Koenig, and N. Ubrich, Low molecular weight heparin nanoparticles: Mucoadhesion and behaviour in Caco-2 cells. Nanotech. 17, 3673 (2006).
13. V. Hoffart, N. Ubrich, C. Simonin, V. Babak, C. Vigneron, M. Hoffman, T. Lecompte, and P. Maincent, Low molecular weight heparin-loaded polymeric nanoparticles: Formulation, characterization, and release characteristics. Drug Dev. Ind. Pharm. 28, 1091 (2002).
14. L. Mu and S. S. Feng, A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS. J. Control Release 86, 33 (2003).
15. X. Shi, Y. Wang, L. Ren, W. Huang, and D. A. Wang, A protein/ antibiotic releasing poly(lactic-co-glycolic acid)/lecithin scaffold for bone repair applications. Int. J. Pharm. 373, 85 (2009).
16. S. I. Park, J. H. Kim, J. H. Lim, and C. O. Kim, Surface-modified magnetic nanoparticles with lecithin for applications in biomedicine. Curr. Appl. Phys. 8, 706 (2008).
17. H. Fessi, F. Puisieux, J. P. Devissaguet, N. Ammoury, and S. Benita, Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int. J. Pharm. 55, R1 (1989).
18. J. Álvarez-Fuentes, L. Martín-Banderas, I. Muñoz-Rubio, M. A. Holgado, and M. Fernández-Arévalo, Development and validation of an RP-HPLC method for CB13 evaluation in several PLGA nanoparticle systems. The Scientific World Journal 2012, 9 (2012).
19. M. Hombreiro-Perez, J. Siepmann, C. Zinutti, A. Lamprecht, N. Ubrich, M. Hoffman, R. Bodmeier, and P. Maincent, Non-degradable microparticles containing a hydrophilic and/or a lipophilic drug: Preparation, characterization and drug release modelling. J. Control Release 88, 413 (2003).
20. V. Belgamwar, V. Shah, and S. J. Surana, Formulation and evaluation of oral mucoadhesive multiparticulate system containing metoprolol tartarate: An in vitro-ex vivo characterization. Curr. Drug Deliv. 6, 113 (2009).
21. K. Gradauer, C. Vonach, G. Leitinger, D. Kolb, E. Fröhlich, E. Roblegg, A. Bernkop-Schnürch, and R. Prassl, Chemical coupling of thiolated chitosan to preformed liposomes improves mucoadhesive properties. Int. J. Nanomed. 7, 2523 (2012).
22. Z. Zhang and S. S. Feng, The drug encapsulation efficiency, in vitro drug release, cellular uptake and cytotoxicity of paclitaxel-loaded poly(lactide)-tocopheryl polyethylene glycol succinate nanoparticles. Biomaterials 27, 4025 (2006).
23. H. Vihola, A. Laukkanen, L. Valtola, H. Tenhu, and J. Hirvonen, Cytotoxicity of thermosensitive polymers poly(N-isopropylacrylamide), poly(N-vinylcaprolactam) and amphiphilically modified poly(N-vinylcaprolactam). Biomaterials 26, 3055 (2005).
24. F. Danhier, N. Lecouturier, B. Vroman, C. Jérôme, J. Marchand-Brynaert, O. Feron, and V. Préat, Paclitaxel-loaded PEGylated PLGA-based nanoparticles: In vitro and in vivo evaluation. J. Control Release 133, 11 (2009).
25. B. Semete, L. Booysen, Y. Lemmer, L. Kalombo, L. Katata, J. Verschoor, and H. S. Swai, In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems. Nanomedicine 6, 662 (2010).
26. J. Pappo and T. H. Ermak, Uptake and translocation of fluorescent latex particles by rabbit Peyer's patch follicle epithelium: A quantitative model for M cell uptake. Clin. Exp. Immunol. 76, 144 (1989).
27. K. Dillen, J. Vandervoort, G. Van den Mooter, and A. Ludwig, Evaluation of ciprofloxacin-loaded Eudragit RS100 or RL100/PLGA nanoparticles. Int. J. Pharm. 314, 72 (2006).
28. J. M. Barichello, M. Morishita, K. Takayama, and T. Nagai, Encapsulation of hydrophilic and lipophilic drugs in PLGA nanoparticles by the nanoprecipitation method. Drug Dev. Ind. Pharm. 25, 471 (1999).
29. S. Fredenberg, M. Wahlgren, M. Reslow, and A. Axelsson, The mechanisms of drug release in poly(lactic-co-glycolic acid)-based drug delivery systems. A review. Int. J. Pharm. 415, 34 (2011).
30. H. Chen, C. Khemtong, X. Yang, X. Chang, and J. Gao, Nanonization strategies for poorly water-soluble drugs. Drug Discov. Today 16, 354 (2011).
31. X. Shi, Y. Wanga, L. Rena, W. Huanga, and D. A. Wang, A protein/antibiotic releasing poly(lactic-co-glycolic acid)/lecithin scaffold for bone repair applications. Int. J. Pharm. 373, 85 (2009).
32. S. Parveen and S. K. Sahoo, Long circulating chitosan/PEG blended PLGA nanoparticles for tumor drug delivery. Eur. J. Pharm. 670, 372 (2001).
33. S. S. Chakravarthi and D. H. Robinson, Enhanced cellular association of paclitaxel delivered in chitosan-PLGA particles. Int. J. Pharm. 409, 111 (2011).
34. A. Bozkir and O. M. Saka, Formulation and investigation of 5-FU nanoparticles with factorial design-based studies. Farmaco 60, 840 (2005).
35. P. R. Karn, Z. Vanic, I. Pepic, and N. Škalko-Basnet, Mucoadhesive liposomal delivery systems: The choice of coating material. Drug Dev. Ind. Pharm. 37, 482 (2011).
36. R. Duncan and L. Izzo, Dendrimer biocompatibility and toxicity. Adv Drug Deliv. Rev. 57, 2215 (2005).
37. A. C. Alhamoruni, K. L. Lee, W. M. Larvin, and S. E. O'Sullivan, Pharmacological Effects of Cannabinoids on the Caco-2 Cell Culture Model of Intestinal Permeability. J. Pharmacol. Exp. Ther. 335, 92 (2010).
38. S. B. Gustafsson, T. Lindgren, M. Jonsson, and S. Jacobsson, Cannabinoid receptor-independent cytotoxic effects of cannabinoids in human colorectal carcinoma cells: synergism with 5-fuorouracil. Cancer Chemother. Pharmacol. 63, 691 (2009).
39. A. Ligresti, T. Bisogno, I. Matias, L. De Petrocellis, M. G. Cascio, V. Cosenza, G. D'Argenio, G. Scaglione, M. Bifulco, I. Sorrentini, and V. Di Marzo, Possible endocannabinoid control of colorectal cancer growth. Gastroenterology 125, 677 (2003).
40. M. L. López-Rodríguez, A. Viso, S. Ortega-Gutiérrez, and I. Díaz-Laviada, Involvement of Cannabinoids in Cellular Proliferation. Mini Rev. Med. Chem. 5, 97 (2005).
41. Y. Sarne, F. Asaf, M. Fishbein, M. Gafni, and O. Keren, The dual neuroprotective-neurotoxic profile of cannabinoid drugs. Brit. J. Pharmacol. 163, 1391 (2011).
42. S. Hart, O. M. Fischer, and A. Ullrich, Cannabinoids induce cancer cell proliferation via tumor necrosis factor alpha-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor. Cancer Res. 64, 1943 (2004).
43. T. E. Rajapaksa, M. Stover-Hamer, X. Fernandez, H. A. Eckelhoefer, and D. D. Lo, Claudin 4-targeted protein incorporated into PLGA nanoparticles can mediate M cell targeted delivery. J. Control Release 142, 196 (2010).
44. K. Tahara, S. Samura, K. Tsuji, H. Yamamoto, Y. Tsukada, Y. Bando, H. Tsujimoto, R. Morishita, and Y. Kawashima, Oral nuclear factor-kB decoy oligonucleotides delivery system with chitosan modified poly(D,L-lactide-co- glycolide) nanospheres for inflammatory bowel disease. Biomaterials 32, 870 (2011).
45. M. Morgen, C. Bloom, R. Beyerinck, A. Bello, W. Song, K. Wilkinson, R. Steenwyk, and S. Shamblin, Polymeric nanoparticles for increased oral bioavailability and rapid absorption using celecoxib as a model of a low-solubility, high-permeability drug. Pharm. Res. 29, 427 (2012).